C. Zhou

1.4k citations

50 papers · 660 indexed · 1 hit paper · h-index 9

Impact in

Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 10%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research

Papers in ⓘ

Oncology 33
- Lung Cancer Research Studies 13
- Colorectal Cancer Treatments and Studies 11
- Cancer Immunotherapy and Biomarkers 11
- HER2/EGFR in Cancer Research 4
Pulmonary and Respiratory Medicine 37
- Lung Cancer Treatments and Mutations 32
- Advanced Breast Cancer Therapies 5
- Brain Metastases and Treatment 4

Co-authors: Byoung Chul Cho (5 shared papers)Yuri Rukazenkov (4 shared papers)Fumio Imamura (4 shared papers)Meng‐Chih Lin (2 shared papers)Riyaz Shah (2 shared papers)Suresh S. Ramalingam (6 shared papers)Aleksandra Markovets (1 shared paper)J. Carl Barrett (1 shared paper)
Journals: Journal of Thoracic Oncology (19 papers)Annals of Oncology (19 papers)Journal of Clinical Oncology (4 papers)Applied Sciences (2 papers)British Journal of Cancer (1 paper)
Partner nations: China United States South Korea

In The Last Decade

C. Zhou

44 papers receiving 651 citations

Hit Papers

align trajectories log scale

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study 2018 · 269 citations

Peers

Countries citing papers authored by C. Zhou

Since Specialization

Citations

This map shows the geographic impact of C. Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Zhou more than expected).

Fields of papers citing papers by C. Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Zhou. The network helps show where C. Zhou may publish in the future.

Co-authors

The 25 scholars most cited alongside C. Zhou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Zhou Line = papers co-authored together C. Zhou links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study Annals of Oncology ·Suresh S. Ramalingam, Yi Cheng, C. Zhou, Y. Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, A. Todd, Aleksandra Markovets, J. Carl Barrett, Juliann Chmielecki, Jhanelle E. Gray Hit paper breakdown →	2018	269
2	ROS1 fusions in Chinese patients with non-small-cell lung cancer Annals of Oncology ·W. Cai, X. Li, Chunxia Su, Lihong Fan, Li-Mou Zheng, K. Fei, C. Zhou, C. Manegold, Gerald Schmid‐Bindert	2013	69
3	Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer Cancer Research ·Xiaowen Huang, Tiantian Sun, Jilin Wang, Xialu Hong, Huimin Chen, Tingting Yan, C. Zhou, Danfeng Sun, Chen Yang, TaChung Yu, Wenyu Su, Wan Du, Hua Xiong	2023	58
4	Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis Annals of Oncology ·Sendhilnathan Ramalingam, J.E. Gray, Yuichiro Ohe, Byoung Chul Cho, Johan Vansteenkiste, C. Zhou, Thanyanan Reungwetwattana, Ying Cheng, B. Chewaskulyong, Riyaz Shah, K.H. Lee, P. Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Rachel Hodge, Yuri Rukazenkov, Jean‐Charles Soria, David Planchard	2019	49
5	2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC Annals of Oncology ·C. Zhou, Meghna Das Thakur, Manoj Srivastava, Wen Zou, Hongjie Xu, M. Ballinger, Enriqueta Felip, Heather A. Wakelee, Nasser K. Altorki, Martin Reck, Rüediger Liersch, Anna Kryzhanivska, M. Harada, Hiroshi Tanaka, John Hamm, Steve McCune, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Silvia Novello	2021	41
6	CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study Annals of Oncology ·Johan Vansteenkiste, Thanyanan Reungwetwattana, Kazuhiko Nakagawa, B.C. Cho, M.A. Cobo Dols, E.K. Cho, A. Bertolini, Sabine Bohnet, C. Zhou, K.H. Lee, Naoyuki Nogami, Isamu Okamoto, Natasha B. Leighl, Rachel Hodge, Astrid McKeown, Andy Brown, Yuri Rukazenkov, S. Ramalingam	2017	27
7	1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results Annals of Oncology ·Luis Paz‐Ares, Yasuhiro Gotô, W.D.T. Lim, Balázs Halmos, Byoung Chul Cho, Manuel Cobo, J.L. González-Larriba, C. Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Bharani Dharan, Martin Reck	2021	22
8	OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations Journal of Thoracic Oncology ·C. Zhou, Suresh S. Ramalingam, B. Li, Jian Fang, T.M. Kim, Sejoong Kim, James Chih‐Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, M.R. García Campelo, Enriqueta Felip, Shu Jin, Veronica Bunn, Jianchang Lin, Hui‐Ming Lin, Minal Mehta, Pasi A. Jänne	2021	21
9	96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial Journal of Thoracic Oncology ·C. Zhou, Shengxiang Ren, J. Chen, Xingxiang Xu, Ying Cheng, G. Chen, Yueyin Pan, Yong Fang, Q. Wang, Yunchao Huang, W. Yao, Ruoyu Wang, X. Li, W. Zhang, YANQIONG ZHANG, Sheng Hu, Renhua Guo, Zaibo Yang, L. Wang	2021	16
10	1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations Annals of Oncology ·James Chih‐Hsin Yang, M. Wang, C-H. Chiu, P-C. Hsu, Paul Mitchell, Chia‐Lun Chang, T.M. Kim, Thomas John, Laurent Greillier, Lyudmila Bazhenova, Enric Carcereny, Alexander I. Spira, Byoung Yong Shim, K.H. Lee, Manuel Cobo, François Ghiringhelli, C. W. Yip, Jie Xiong, Pasi A. Jänne, C. Zhou	2023	7
11	Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC Annals of Oncology ·C. Zhou, You Lü, S.-W. Kim, Thanyanan Reungwetwattana, Jianying Zhou, Y. Zhang, Jianxing He, Jin‐Ji Yang, Ying Cheng, S.H. Lee, L. Bu, Tingting Xu, Lei Yang, Chenhao Wang, Peter N. Morcos, Emmanuel Mitry, Tian Liu, L. Zhang	2018	7
12	OA10.07 Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial Journal of Thoracic Oncology ·C. Zhou, Mingdao Hu, Xiaofan Zhu, Yihua Sun, Xin-Jie Lu, J. Wang, M. Wang, Ying Cheng, Y. Chen, Yanqiu Zhao, Yuankai Shi, You Lu, Meiqi Shi, H. Zhang, X. Huang, Zehao Wang, Zhangfan Ding, Haodong Li, Guangyu CHEN, Yi‐Long Wu	2018	6
13	A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT). Journal of Clinical Oncology ·Yi‐Long Wu, C. Zhou, Yin Cheng, Sheng-Feng Lu, Guan Xu Chen, Chen Huang, Yanjie Huang, Hong-Ya Yan, J. Yang, (unknown)	2011	6
14	Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC) Annals of Oncology ·C. Zhou, You Lü, S.-W. Kim, Thanyanan Reungwetwattana, Jianying Zhou, Y. Zhang, Jianxing He, Jin‐Ji Yang, Ying Cheng, S.H. Lee, L. Bu, Tingting Xu, Lei Yang, Chenhao Wang, Peter N. Morcos, Emmanuel Mitry, Z. Li	2018	5
15	81P Radiation resistance induced immunity evasion by evoking PD-L1 expression Journal of Thoracic Oncology ·Xiaonan Gong, X. Li, C. Zhou	2016	5
16	CNS response to osimertinib in Asian-Pacific patients (pts) with T790M-positive advanced NSCLC: data from an open-label Phase II trial (AURA17) Annals of Oncology ·C. Zhou, Ying Cheng, You Lü, Meiqi Shi, J-Y. Han, M. Wang, S-W. Kim, J. Wang, Y. Chen, Yi‐Long Wu	2017	5
17	P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS Journal of Thoracic Oncology ·K. Park, E. Tan, Kenneth J. O’Byrne, L. Zhang, Michael Boyer, Tony Mok, V. Hirsh, James Chih‐Hsin Yang, Martin Schüler, Nobuyuki Yamamoto, Lecia V. Sequist, Yi‐Long Wu, C. Zhou, E. Ehrnrooth, Angela Märten, Wenbo Tang, L. Paz-Ares	2017	4
18	MA13.07 GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC Journal of Thoracic Oncology ·C. Zhou, Z. Wang, Yehuan Sun, L. Cao, Z. Ma, Rong Wu, Yan Yu, W. Yao, Huijie Wang, J. Chen, Wu Zhuang, Jiuwei Cui, Xudong Chen, You Lü, Hong Shen, Ruanqi Chen, Xiaojian Xu, Dongmei Lu, J. Wang, Jin‐Kui Yang	2021	4
19	MA13.06 Deciphering the Characterization of Tumor Microenvironment in EGFR-Mutated Non-Small Cell Lung Cancer Journal of Thoracic Oncology ·Meng Qiao, Tao Jiang, Shengxiang Ren, C. Zhou	2021	3
20	1264MO IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC) Annals of Oncology ·Nasser K. Altorki, Martin Reck, H. Wakelee, Enriqueta Felip, Eric Vallières, Rüdiger Liersch, Satoshi Oizumi, Hiroshi Tanaka, Silvia Novello, Steve McCune, H. Li, Luciana Molinero, Sören Müller, Elizabeth Bennett, B.J. Gitlitz, Virginia McNally, M. Ballinger, Barzin Y. Nabet, Minu K. Srivastava, C. Zhou	2023	3

About C. Zhou

C. Zhou is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Ecological Modeling, having authored 50 papers that have together received 660 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Research Studies (13 papers), Colorectal Cancer Treatments and Studies (11 papers), Cancer Immunotherapy and Biomarkers (11 papers), Advanced Breast Cancer Therapies (5 papers), HER2/EGFR in Cancer Research (4 papers), Cancer Genomics and Diagnostics (4 papers) and Brain Metastases and Treatment (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (551 citations), Oncology (449 citations), Cancer Research (153 citations), Molecular Biology (202 citations) and Pathology and Forensic Medicine (47 citations). C. Zhou has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Byoung Chul Cho, Yuri Rukazenkov, Fumio Imamura, Meng‐Chih Lin, Riyaz Shah, Suresh S. Ramalingam, Aleksandra Markovets, J. Carl Barrett, Jhanelle E. Gray and Y. Ohe. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Journal of Clinical Oncology, Applied Sciences and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact